ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2010
Mechanism of neuroinflammation: enhanced cytotoxicity and IL-17 production via CD46 binding.
Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- CD46 TREM1 regulates the autophagy marker LC3B ATG5 in oral squamous cell carcinoma.Frontiers in oncology · 2025Article
- The Development of Epilepsy Following CNS Viral Infections: Mechanisms.Current neurology and neuroscience reports · 2024Review
- Relationship between Hypoxic and Immune Pathways Activation in the Progression of Neuroinflammation: Role of HIF-1α and Th17 Cells.International journal of molecular sciences · 2023Review
- Article
- The role of the complement system in Multiple Sclerosis: A review.Frontiers in immunology · 2022Review
- Article
- Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation.Clinical microbiology reviews · 2020Review
- Roseolovirus-associated encephalitis in immunocompetent and immunocompromised individuals.Journal of neurovirology · 2017Review
- Immunomodulation and immunosuppression by human herpesvirus 6A and 6B.Future virology · 2013Article
- Possible role of human herpesvirus 6 as a trigger of autoimmune disease.TheScientificWorldJournal · 2013Review
- Human CD4+ T cell response to human herpesvirus 6.Journal of virology · 2012Article
- CD46 processing: a means of expression.Immunobiology · 2012Review
- CD46 in innate and adaptive immunity: an update.Clinical and experimental immunology · 2011Review
- Viral infections of the central nervous system: pathogenesis to therapeutics.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The membrane co-factor protein CD46 is the cellular receptor for a number of pathogens including the human herpesvirus 6 (HHV-6). In addition to its function as an inhibitory complement receptor, engagement of CD46 in the context of T-cell receptor (TCR) signaling influences T-cell activation. Simultaneous cross-linking of the CD3/CD46 molecules led to differentiation of a unique population of CD4+ T-cell subset characterized by enhanced expressions of IFN-gamma, IL-10, granzyme B, adhesion molecule MAdCAM-1 (alpha-4-beta-7), surface-bound cytokine LIGHT, and chemokine receptor CCR9. Multiple sclerosis is a chronic inflammatory neurodegenerative disorder of the central nervous system (CNS) with unknown etiology. The HHV-6 is a candidate pathogen in MS and uses the CD46 molecule as its receptor. We hypothesize that binding of the HHV-6 glycoprotein to CD46 may trigger a pro-inflammatory response that could contribute to CNS tissue damage. To address this question, we examined immunological parameters such as proliferation, cytokine production and cytotoxic functions in CD4+ T cells of healthy individuals and MS patients following CD3/CD46 co-engagement by using anti-CD3 and anti-CD46 monoclonal antibodies as surrogates to mimic T-cell receptor and CD46 signaling. Our results demonstrated that CD3/CD46 cross-linking induced expression of IL-1beta and IL-17A in multiple sclerosis patient T cells. Additionally, increase in transient surface expression of lysosomal associated protein CD107a suggested enhanced CD4+ T-cell cytotoxic functions following CD3/CD46 co-stimulation. Collectively, this study demonstrated evidence to suggest a potential mechanism of virus-induced neuroinflammation that may be involved in MS disease pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.